These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 27411694)

  • 1. Pregnancy Experience: Nonclinical Studies and Pregnancy Outcomes in the Daclizumab Clinical Study Program.
    Gold R; Stefoski D; Selmaj K; Havrdova E; Hurst C; Holman J; Tornesi B; Akella S; McCroskery P
    Neurol Ther; 2016 Dec; 5(2):169-182. PubMed ID: 27411694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of Pregnancy Outcomes Following Exposure to Intramuscular Interferon Beta-1a: The AVONEX
    Weinstock-Guttman B; Ross AP; Planton J; White K; Pandhi A; Greco A; Kumar A; Everage N; Vignos M
    Drugs Real World Outcomes; 2023 Dec; 10(4):503-511. PubMed ID: 37737962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delayed-Release Dimethyl Fumarate and Pregnancy: Preclinical Studies and Pregnancy Outcomes from Clinical Trials and Postmarketing Experience.
    Gold R; Phillips JT; Havrdova E; Bar-Or A; Kappos L; Kim N; Thullen T; Valencia P; Oliva L; Novas M; Li J; Sweetser MT; Kurukulasuriya N; Viglietta V; Fox RJ
    Neurol Ther; 2015 Dec; 4(2):93-104. PubMed ID: 26662361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pregnancy outcomes and postpartum relapse rates in women with RRMS treated with alemtuzumab in the phase 2 and 3 clinical development program over 16 years.
    Oh J; Achiron A; Celius EG; Chambers C; Derwenskus J; Devonshire V; Hellwig K; Hutton GJ; McCombe P; Moore M; Rog D; Schneider JR; Simm RF; Sousa L; Vincent SG; Chung L; Daizadeh N; Mitchell C; Compston DAS;
    Mult Scler Relat Disord; 2020 Aug; 43():102146. PubMed ID: 32498033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pregnancy Outcomes During the Clinical Development Program of Cladribine in Multiple Sclerosis: An Integrated Analysis of Safety.
    Giovannoni G; Galazka A; Schick R; Leist T; Comi G; Montalban X; Damian D; Dangond F; Cook S
    Drug Saf; 2020 Jul; 43(7):635-643. PubMed ID: 32447743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
    Kappos L; Wiendl H; Selmaj K; Arnold DL; Havrdova E; Boyko A; Kaufman M; Rose J; Greenberg S; Sweetser M; Riester K; O'Neill G; Elkins J
    N Engl J Med; 2015 Oct; 373(15):1418-28. PubMed ID: 26444729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of pregnancy outcomes from the Tysabri® (natalizumab) pregnancy exposure registry: a global, observational, follow-up study.
    Friend S; Richman S; Bloomgren G; Cristiano LM; Wenten M
    BMC Neurol; 2016 Aug; 16(1):150. PubMed ID: 27552976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hydrocephalus and the reproductive health of women: the medical implications of maternal shunt dependency in 70 women and 138 pregnancies.
    Liakos AM; Bradley NK; Magram G; Muszynski C
    Neurol Res; 2000 Jan; 22(1):69-88. PubMed ID: 10672583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial.
    Giovannoni G; Gold R; Selmaj K; Havrdova E; Montalban X; Radue EW; Stefoski D; McNeill M; Amaravadi L; Sweetser M; Elkins J; O'Neill G;
    Lancet Neurol; 2014 May; 13(5):472-81. PubMed ID: 24656609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pregnancy outcomes in female multiple sclerosis patients exposed to intramuscular interferon beta-1a or peginterferon beta-1a reported in a German Patient Support Programme - results from the non-interventional post-authorization safety study PRIMA.
    Klehmet J; Begus-Nahrmann Y; Taipale K; Niemczyk G; Rehberg-Weber K
    Ther Adv Neurol Disord; 2023; 16():17562864231214041. PubMed ID: 38107443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial.
    Gold R; Giovannoni G; Selmaj K; Havrdova E; Montalban X; Radue EW; Stefoski D; Robinson R; Riester K; Rana J; Elkins J; O'Neill G;
    Lancet; 2013 Jun; 381(9884):2167-75. PubMed ID: 23562009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of daclizumab versus interferon beta-1a on patient-reported outcomes in relapsing-remitting multiple sclerosis.
    Liu Y; Vollmer T; Havrdova E; Riester K; Lee A; Phillips G; Wang P; Sabatella G
    Mult Scler Relat Disord; 2017 Jan; 11():18-24. PubMed ID: 28104250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pregnancy outcomes during treatment with interferon beta-1a in patients with multiple sclerosis.
    Sandberg-Wollheim M; Frank D; Goodwin TM; Giesser B; Lopez-Bresnahan M; Stam-Moraga M; Chang P; Francis GS
    Neurology; 2005 Sep; 65(6):802-6. PubMed ID: 16093457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Return of fertility following discontinuation of Norplant-II subdermal implants. ICMR Task Force on Hormonal Contraception.
    Buckshee K; Chatterjee P; Dhall GI; Hazra MN; Kodkany BS; Lalitha K; Logambal A; Manchanda P; Nanda UK; RaiChoudhury G
    Contraception; 1995 Apr; 51(4):237-42. PubMed ID: 7796589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of daclizumab beta in patients with relapsing multiple sclerosis in a 5-year open-label study (EXTEND): final results following early termination.
    Kappos L; Cohan S; Arnold DL; Robinson RR; Holman J; Fam S; Parks B; Xiao S; Castro-Borrero W
    Ther Adv Neurol Disord; 2021; 14():1756286420987941. PubMed ID: 33737954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta.
    Wynn D; Kaufman M; Montalban X; Vollmer T; Simon J; Elkins J; O'Neill G; Neyer L; Sheridan J; Wang C; Fong A; Rose JW;
    Lancet Neurol; 2010 Apr; 9(4):381-90. PubMed ID: 20163990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Teenage pregnancy in Scotland: trends and risks.
    Rosenberg K; McEwan HP
    Scott Med J; 1991 Dec; 36(6):172-4. PubMed ID: 1805377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
    Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pregnancy Outcomes After Exposure to Certolizumab Pegol: Updated Results From a Pharmacovigilance Safety Database.
    Clowse MEB; Scheuerle AE; Chambers C; Afzali A; Kimball AB; Cush JJ; Cooney M; Shaughnessy L; Vanderkelen M; Förger F
    Arthritis Rheumatol; 2018 Sep; 70(9):1399-1407. PubMed ID: 29623679
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induced abortion. Effects of marital status, age and parity on choice of pregnancy termination.
    Skjeldestad FE; Borgan JK; Daltveit AK; Nymoen EH
    Acta Obstet Gynecol Scand; 1994 Mar; 73(3):255-60. PubMed ID: 8122509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.